uniQureQURE
QURE
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
292% more call options, than puts
Call options by funds: $51.5M | Put options by funds: $13.2M
277% more capital invested
Capital invested by funds: $195M [Q3] → $734M (+$539M) [Q4]
33% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 27
5% more funds holding
Funds holding: 130 [Q3] → 137 (+7) [Q4]
4.72% more ownership
Funds ownership: 80.64% [Q3] → 85.36% (+4.72%) [Q4]
27% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 48
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
147%
upside
Avg. target
$41
316%
upside
High target
$70
619%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Chardan Capital Daniil Gataulin 24% 1-year accuracy 4 / 17 met price target | 291%upside $38 | Buy Maintained | 1 Apr 2025 |
HC Wainwright & Co. Patrick Trucchio 0% 1-year accuracy 0 / 41 met price target | 619%upside $70 | Buy Reiterated | 4 Mar 2025 |
Wells Fargo Yanan Zhu 6% 1-year accuracy 1 / 16 met price target | 208%upside $30 | Equal-Weight Maintained | 28 Feb 2025 |
RBC Capital Luca Issi 18% 1-year accuracy 10 / 55 met price target | 147%upside $24 | Outperform Reiterated | 21 Jan 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
1 month ago
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
UniQure (QURE) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.53 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~
Positive
Seeking Alpha
1 month ago
uniQure N.V.: A Potential Huntington's Play
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Positive
Seeking Alpha
1 month ago
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025.
Positive
Benzinga
1 month ago
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
CSL Limited CSLLY and uniQure Inc QURE announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of Hemgenix (etranacogene dezaparvovec-drlb) for adults hemophilia B patients.
Neutral
PRNewsWire
1 month ago
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX in the treatment of hemophilia B Phase 3 HOPE-B data showed that a one-time treatment with HEMGENIX provided long-term bleed protection as mean adjusted annualized bleeding rate (ABR) for all bleeds was reduced by approximately 90% from lead-in as compared to year four KING OF PRUSSIA, Pa. , Feb. 7, 2025 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the four-year results from the pivotal HOPE-B study confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) for adults living with hemophilia B.
Neutral
GlobeNewsWire
1 month ago
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~
Neutral
GlobeNewsWire
2 months ago
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~
Neutral
GlobeNewsWire
2 months ago
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $75 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 661,764 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 10, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Charts implemented using Lightweight Charts™